title: Long-term disruption of maternal glucose homeostasis induced by prenatal glucocorticoid treatment correlates with miR-29 upregulation.
abstract: Excess of glucocorticoids (GCs) during pregnancy is strongly associated with the programming of glucose intolerance in the offspring. However, the impact of high GC levels on maternal metabolism is not clearly documented. This study aimed to test the hypothesis that mothers exposed to elevated levels of GCs might also display long-term disturbances in glucose homeostasis. Dexamethasone (DEX) was administered noninvasively to the mothers via drinking water between the 14th and the 19th days of pregnancy. Mothers were subjected to glucose and insulin tolerance tests at 1, 2, 3, 6, and 12 mo postweaning. Pregnant rats not treated with DEX and age-matched virgin rats were used as controls. Pancreatic islets were isolated at the 20th day of pregnancy and 12 mo postweaning in order to evaluate glucose-stimulated insulin secretion. The expression of the miR-29 family was also studied due to its responsiveness to GCs and its well-documented role in the regulation of pancreatic β-cell function. Rats treated with DEX during pregnancy presented long-term glucose intolerance and impaired insulin secretion. These changes correlated with 1) increased expression of miR-29 and its regulator p53, 2) reduced expression of syntaxin-1a, a direct target of miR-29, and 3) altered expression of genes related to cellular senescence. Our data demonstrate that the use of DEX during pregnancy results in deleterious outcomes to the maternal metabolism, hallmarked by reduced insulin secretion and glucose intolerance. This maternal metabolic programming might be a consequence of time-sustained upregulation of miR-29s in maternal pancreatic islets.
authors.affiliation: Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil;
authors.forename: Patrícia R
authors.initials: PR
authors.lastname: Gomes
authors.forename: Maria F
authors.initials: MF
authors.lastname: Graciano
authors.forename: Lucas C
authors.initials: LC
authors.lastname: Pantaleão
authors.forename: André L
authors.initials: AL
authors.lastname: Rennó
authors.forename: Sandra C
authors.initials: SC
authors.lastname: Rodrigues
authors.forename: Licio A
authors.initials: LA
authors.lastname: Velloso
authors.forename: Márcia Q
authors.initials: MQ
authors.lastname: Latorraca
authors.forename: Angelo R
authors.initials: AR
authors.lastname: Carpinelli
authors.forename: Gabriel F
authors.initials: GF
authors.lastname: Anhê
authors.forename: Silvana
authors.initials: S
authors.lastname: Bordin
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000032:analysis / Q000378:metabolism*; D016922:Cellular Senescence / Q000235:genetics; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005865:Gestational Age; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D018149:Glucose Intolerance / Q000209:etiology; D005951:Glucose Tolerance Test; D006706:Homeostasis / Q000187:drug effects*; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D035683:MicroRNAs / Q000235:genetics*; D011247:Pregnancy; D011295:Prenatal Care; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D050827:Syntaxin 1 / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000235:genetics; D015854:Up-Regulation / Q000187:drug effects*
chemical_list: D001786:Blood Glucose; D005938:Glucocorticoids; D007328:Insulin; C526366:MIRN29 microRNA, rat; D035683:MicroRNAs; D012333:RNA, Messenger; D050827:Syntaxin 1; D016159:Tumor Suppressor Protein p53; D003907:Dexamethasone
keywords: cellular senescence; dexamethasone; insulin secretion; miR-29; pregnancy